Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib

Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib - The usefulness of switching to celecoxib in patients with NSAIDs-induced gastrointestinal mucosal injury

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004271

Enrollment

100

Registered

2010-09-27

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis (RA) NSAIDs-induced gastrointestinal mucosal injury

Interventions

Japanese rheumatic patients who have been treated with NSAIDs for twelve or more weeks are switched to CEL (400mg/day). Upper GI endoscopy is conducted before and after administration of CEL. Patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. RA patients receiving traditional NSAIDs for twelve or more month 2. Patients of 20 years or more regardless of their gender, or being outpatients or not 3. Patients giving informed consent

Exclusion criteria

Exclusion criteria: Patients with 1. Gastrectomy or vagotomy 2. Malignancy 3. Severe hepatic dysfunction 4. Severe renal dysfunction 5. Severe cardiac dysfunction 6. hematologic disease 7. Patients showing hypersensitive reaction to celecoxib or one member of the sulfonamide class 8. Patients being pregnant or plan to become pregnant during treatment 9. Patients who are regarded as inadequate subject by physician in charge

Design outcomes

Primary

Measure	Time frame
Changes in incidence of gastroduodenal mucosal injury.	—

Secondary

Measure	Time frame
Incidence of gastroduodenal mucosal injury in patients with long-term NSAIDs therapy Changes in disease activity measures of rheumatoid arthritis after switching to celecoxib Adverse side effect	—

Countries

Japan

Contacts

Public ContactYoko Amino

Hoshigaoka Koseinenkin Hospital Dept. of Clinical Trial Management

072-840-2641

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026